Allurion Technologies (NYSE:ALUR) versus TriSalus Life Sciences (NASDAQ:TLSI) Head to Head Comparison

Allurion Technologies (NYSE:ALUR) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, earnings, profitability and institutional ownership.

Profitability

This table compares Allurion Technologies and TriSalus Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Allurion Technologies	-199.96%	N/A	-77.13%
TriSalus Life Sciences	-60.85%	N/A	-69.91%

Volatility & Risk

Allurion Technologies has a beta of -0.13, indicating that its stock price is 113% less volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500.

Institutional & Insider Ownership

21.4% of Allurion Technologies shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 8.1% of Allurion Technologies shares are owned by insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Allurion Technologies and TriSalus Life Sciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allurion Technologies	$17.21 million	0.62	-$7.20 million	($2.03)	-0.35
TriSalus Life Sciences	$45.15 million	4.26	-$39.23 million	($1.41)	-2.22

Allurion Technologies has higher earnings, but lower revenue than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings for Allurion Technologies and TriSalus Life Sciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allurion Technologies	1	1	1	0	2.00
TriSalus Life Sciences	1	1	2	0	2.25

Allurion Technologies currently has a consensus target price of $3.00, suggesting a potential upside of 322.06%. TriSalus Life Sciences has a consensus target price of $7.50, suggesting a potential upside of 139.62%. Given Allurion Technologies’ higher probable upside, research analysts clearly believe Allurion Technologies is more favorable than TriSalus Life Sciences.

Summary

TriSalus Life Sciences beats Allurion Technologies on 9 of the 13 factors compared between the two stocks.

About Allurion Technologies

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.